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Abstract 
Aim: To investigate the efficacy and safety of electromyography (EMG)- and palpation-guided botulinum toxin type 
A injection in cervical dystonia (CD) patients.
Methods: In this randomized, controlled trial, 68 CD patients were randomly allocated to two groups, receiving botu-
linum toxin type A injections guided by either palpation (Group A) or EMG (Group B). The primary endpoint is defined 
as the difference in the Tsui score between groups at 16 weeks. The secondary endpoints were the visual analog scale 
(VAS) and Hospital Anxiety and Depression Scale (HADS) scores and Clinical and Patient Global Impression of Change 
(CGIC and PGIC).
Results: Sixty-five patients completed the study. No significant difference was observed in the Tsui score between 
groups A and B at 4, 8, and 12 weeks after treatment (p > 0.05). However, 16 weeks after treatment, the Tsui score of 
group A was significantly higher than that of group B. For both groups, the degree of pain at each time point dur-
ing follow-up significantly reduced after treatment. However, no significant difference was observed in VAS scores 
between the two groups. Interestingly, the patient HADS score decreased without statistical significance 8 weeks fol-
lowing treatment. No significant difference in HADS scores was observed between the two groups. Additionally, there 
was no significant difference in PGIC and CGIC between the two groups. However, CGIC was significantly higher than 
PGIC. No significant difference in adverse reactions was observed between groups. CD patients treated with EMG 
guidance experienced a significantly more pain at the injection site but a significantly lower adverse event occurrence 
rate of dysphagia when compared to CD patients treated with palpation guidance only.
Conclusions: CD patients treated with EMG guidance experienced a prolonged benefit as measured by the Tsui 
scale when compared to CD patients treated with palpation guidance alone. EMG-guided injection resulted in a lower 
incidence of dysphagia and higher incidence of discomfort at the injection site than palpation-guided injection.
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Background
Cervical dystonia (CD) is the most common form of focal 
dystonia. It is characterized by involuntary muscular con-
tractions resulting in abnormal neck and shoulder move-
ments and postures, which can involve tremor and pain. 
This disorder is profoundly distressing and can negatively 
impact the patient’s quality-of-life (Comella and Bhatia 
2015). CD is more common in women than in men and 
occurs in 28–183 individuals per 100,000 (Defazio et al. 
2013).
Botulinum toxin type A is a serotype (A, B, C1, C2, 
D, E, F, and G) of botulinum neurotoxin derived from 
Clostridium botulinum (Setler 2002). It was first used 
clinically in the 1980s for the treatment of strabismus. 
Since its introduction, botulinum toxin type A has been 
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used for a variety of clinical conditions, including hemi-
facial spasm, Meige’s syndrome, migraine, and CD. Intra-
muscular injection of botulinum toxin type A is effective 
and well-tolerated for CD treatment (Truong et al. 2005) 
and has therefore been recommended as a first-line ther-
apy under current treatment guidelines (Albanese et  al. 
2011; Simpson et al. 2016).
Numerous studies have focused on the optimal dose, 
short-term and long-term efficacies, and botulinum toxin 
(BT) serotype efficacy for the treatment of CD (Pappert 
et al. 2008; Dressler et al. 2013; Poewe et al. 1998). How-
ever, few studies have evaluated BT injection technique 
for the treatment of CD (Simpson et  al. 2016; Walker 
et al. 2015; Comella et al. 1992). Currently, most clinical 
practices inject BT using palpation for guidance. Other 
commonly used injection techniques include electro-
myography (EMG), electrical stimulation, or ultrasound 
guidance (Walker et  al. 2015). Therefore, we compared 
the efficacy and safety of EMG- and palpation-guided 
botulinum toxin type A injection in CD patients.
Methods
Study design
This is a prospective, randomized, single-blind, clinical 
trial evaluating response of CD treated with botulinum 
toxin A administered using EMG guidance versus palpa-
tion. The ethics review boards approved the study proto-
col. The goal, procedure, and safety aspects of the study 
were explained to each patient. All patients provided 
written informed consent to participate in the study.
All treatments were administered by a neurologist 
who did not participate in the randomization and inves-
tigation procedures. Physician raters were blinded to 
treatment assignment. After obtaining baseline measure-
ments, patients meeting the study criteria were randomly 
divided into two groups. Group A received botulinum 
toxin type A injections guided by palpation, whereas 
group B received botulinum toxin type A injections 
guided by EMG. We allocated patients to one of the two 
groups using a restricted randomization scheme gener-
ated by SPSS. The overall duration of the study for each 
patient was 16  weeks, and follow-up visits were con-
ducted every 4  weeks after the injection. Patients were 
free to discontinue the trial at any time during the study. 
Patients who were on antispasmodic and/or antidepres-
sant medications were requested to remain on baseline 
medication doses for the duration of the study.
Study participants
Patients were recruited at the First Affiliated Hospital 
of Zhengzhou University, the Second Hospital of Hebei 
University and the Second People’s Hospitla of Liaocheng 
between February 2014 and March 2015. Criteria for 
entry into the study were: (1) patients aged between 18 
and 80 years, (2) primary focal CD without other dysto-
nia (diagnosis made by clinical symptoms and EMG), (3) 
CD history ≥6 months, (4) no previous history of botu-
linum toxin therapy or a minimum interval of 18 weeks 
since the last injection, and (5) TSUI score ≥9 at baseline.
Exclusion criteria included patients with any medi-
cal condition or use of any agent that might put them at 
increased risk if exposed to botulinum toxin type A (e.g. 
neuromuscular disorders or agents that might interfere 
with neuromuscular function), infections or skin prob-
lems at the injection site, patients who weighed less than 
45 kg, or had pure anterocollis. Women of childbearing 
age were required to have a negative pregnancy test result 
prior to injection. Furthermore, women who were preg-
nant, nursing, or planning a pregnancy during the study, 
or who were unable or unwilling to use a reliable form of 
contraception during the study were also excluded.
Treatments
All treatments were administered in the treatment room 
of the Department of Neurology, which is equipped with 
all the necessary facilities in case of severe reactions or 
emergencies.
Botulinum toxin type A (100  U of C. botulinum type 
A neurotoxin complex, 5 mg gelatin, 25 mg dextran, and 
25 mg saccharose) was obtained from Lanzhou Biologi-
cal Products Institute (Hengli, Lanzhou, China). Each vial 
was diluted in 2 mL of saline solution (0.9 %) as recom-
mended by the manufacturer. Injection doses for each 
muscle were as follows: 25–100  U for the sternocleido-
mastoid muscle, 50–100 U for the splenius capitis mus-
cle, 25–100 U for the trapezius muscle, 25–60 U for the 
levator scapulae, and 10–25  U for the anterior, middle 
and posterior scalene muscle. The specific injection dose 
for each muscle was determined based on clinical condi-
tions and controlled within the above ranges by the phy-
sician administering the injections.
In the group receiving injection guided by palpation, 
the physician identified a bony landmark and used palpa-
tion to identify the target muscles. Target muscles were 
selected based on the following aspects: (1) posture of 
the head and the neck at rest and during passive and vol-
untary movement, as well as biomechanical analysis of 
involuntary movement; (2) the location of neck pain or 
traction at rest and during passive and voluntary move-
ment; (3) and the site of hypertrophy or stiffness of the 
neck muscles identified by observation or palpation. The 
injections were administered using a 1-mL syringe with a 
0.45-mm needle.
In the group receiving injection guided by EMG, a spe-
cial EMG electrode with a hollow core and insulated exte-
rior was employed, with the recording lead connected 
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to the EMG recorder and the tail end connected to the 
injection syringe. Injection sites were selected based on 
the following aspects: (1) spontaneous tonic activity or 
muscle electrical activity in quartiles at rest; (2) sponta-
neous low to median frequency (4–9  Hz) tremor-type 
electrical activity; (3) presence of excitation interference 
by antagonists on voluntary movements; (4) and sensory 
maneuvers that can reduce EMG activity in dystonia.
Efficacy and safety measures
The primary endpoint of the study was the Tsui score at 
16 weeks (Tsui et al. 1986). The Tsui score was assessed 
using standardized conditions (at least 1-min assess-
ment with the patient sitting in a comfortable chair, eyes 
open, making a subjective effort to relax the head and 
neck, and refraining from sensory maneuvers during the 
assessment).
The secondary endpoints were head and neck region 
pain as assessed based on the visual analog scale (VAS) 
score every 4 weeks, symptoms of anxiety and depression 
as assessed by the Hospital Anxiety and Depression Scale 
(HADS) at 8 weeks, and overall response to treatment as 
assessed by the Clinical and Patient Global Impression of 
Change (CGIC and PGIC, respectively) scale at 16 weeks. 
HADS is a self-assessment scale for evaluating the cur-
rent severity of depression and anxiety. A HADS score >7 
represents the presence of anxiety or depression. Higher 
scores reflect marked impairment. PGIC is a self-evalua-
tion of the patient’s overall change since the start of the 
study on a 7-point scale (1, very much improved; 2, much 
improved; 3, minimally improved; 4, no change; 5, min-
imally worse; 6, much worse; 7, very much worse), and 
was obtained at the end of the study.
Safety was evaluated based on the occurrence of 
adverse reactions. Adverse events were assessed at each 
clinic visit using a combination of open questioning and 
a checklist of ten conditions (Wissel et al. 2001) (dyspha-
gia, dry mouth, voice changes, neck muscle weakness, 
tiredness, respiratory difficulties, discomfort at injection 
site, visual difficulties, jaw weakness, and limb weakness) 
commonly considered to be related to botulinum toxin 
type A use. Once an adverse reaction occurred, the time 
of the adverse reaction occurrence, its duration time, the 
occurrence frequency, severity, whether treatment was 
required, and the treatment outcome were recorded.
Statistical analysis
The sample size was estimated from treatment differ-
ences using similar previous CD studies (Comella et  al. 
1992). This sample size would provide 80 % power at two-
sided significance level of 0.05.
All analyses were performed on the intent-to-treat 
(ITT) population, and all statistical testing was two-sided. 
The quantitative data were assessed using the mean and 
standard deviation. The t test was performed to compare 
the age, duration of disease, Tsui score between groups 
at 4, 8, 12 and 16 weeks, VAS every 4 weeks, and HADS 
score between the two groups at 8 weeks. The Chi square 
test was performed to assess differences in gender, PGIC 
and CGIC distribution at 16  weeks, and the proportion 
of adverse reactions between two groups. The SPSS 13.0 
software package was used for statistical evaluation, and 
a p value <0.05 was considered statistically significant.
Results
Patient characteristics
The recruitment period was between February 2014 
and March 2015, with a 16-week follow-up period after 
the last patient was enrolled. Ninety-six patients were 
screened, and 68 were randomized (32 guided by palpa-
tion, 36 guided by EMG). Sixty-five patients completed 
the study. A flow diagram of the study is shown in Fig. 1. 
There were no significant between-group differences in 
demographic data, baseline clinical characteristics, or 
botulinum toxin type A dose (Table 1). 
Efficacy
No significant differences were observed in the Tsui score 
between group A and group B at 4, 8, and 12 weeks after 
treatment (p > 0.05). However, 16 weeks post-treatment, 
the Tsui score in group A was significantly higher than 
that in group B (p < 0.05) (Fig. 2).
The pain associated with CD at baseline was similar 
in both groups, with 12/32 (37.5  %) group A patients 
and 14/36 (38.9 %) group B patients being pain-free. No 
significant difference in degree of pain was observed 
between the two groups at baseline or at any time point 
during follow-up (p > 0.05) (Table 2), although for both 
groups, the degree of pain at each time point significantly 
reduced compared to that at pre-treatment conditions 
(p < 0.05).
No significant difference in HADS score was observed 
between group A and group B 8  weeks post-treatment 
(p > 0.05). Varying degrees of anxiety occurred in 54.4 % 
(37/68) of patients, and varying degrees of depression 
were observed in 64.7 % (44/68) of patients. The HADS 
scores decreased at 8  weeks post-botulinum toxin type 
A treatment, but this difference was not significant 
(p > 0.05).
Using the patient-rated PGIC, 59.3  % (19/32) of 
patients in group A rated their overall condition as “very 
much improved” or “much improved,” whereas 61.1  % 
(22/36) of patients in group B rated their condition as 
“very much improved” or “much improved” 16  weeks 
after treatment. There was no significant difference in 
PGIC findings between groups (p  >  0.05). The CGIC 
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findings paralleled the PGIC results. However, compared 
to PGIC findings, higher percentages of patients, 71.9 % 
(23/32) and 72.2 % (26/36), respectively, were rated “very 
much improved” or “much improved.” No significant dif-
ference was observed between groups. In both groups, 
a significantly higher proportion of patients “very much 
improved” or “much improved” using the CGIC than 
using the PGIC (p < 0.05).
Safety
Adverse reactions occurred in 53.1 % (17/32) and 52.8 % 
(19/36) of patients in group A and group B after treat-
ment, respectively. However, the incidence of dysphagia 
in group A was significantly higher than that in group 
B (p < 0.05). A significantly higher incidence of discom-
fort at the injection site occurred in group B, than that in 
group A (p < 0.05) (Table 3). All adverse events occurred 
within 2  weeks and completely disappeared within 
8  weeks. Adverse reactions during the trial were very 
mild, and no special treatment was required.
One patient in group A and 2 patients in group B dis-
continued the study owing to lack of efficacy or lack of 
follow-up.
Discussion
Botulinum toxin type A inhibits peripheral acetylcholine 
release by cleaving synaptosomal-associated proteins 
of 25  kDa (SNAP-25) in the presynaptic membrane of 
cholinergic nerve terminals, inducing chemical dener-
vation of muscles and relieving symptoms of dystonia. 
After botulinum toxin type A injection, new motor end 
plates are formed by the sprouting of nerve terminals. 
Therefore, long-term and repeated botulinum toxin type 
A injection is required for the treatment of CD, making 
it crucial to compare the efficacies of various injection 
techniques. There are several common injection tech-
niques for botulinum toxin type A, including the use of 
palpation, EMG, electrical stimulation, and ultrasound 
guidance.
Despite controversies regarding the use of botulinum 
toxin type A treatment for dystonia, the majority of stud-
ies indicate that injection guided by palpation and EMG 
result in comparable outcomes. In the present study, 
the efficacy and safety of botulinum toxin type A injec-
tion guided by the two techniques, palpation and EMG, 
were compared in the treatment of CD patients. In agree-
ment with previous findings (Truong et al. 2005; Hallett 
et  al. 2013), clinical symptoms of patients significantly 
improved following botulinum toxin type A injection, 
and the Tsui score significantly decreased compared to 
baseline. Few studies have evaluated the effect of injec-
tion techniques on CD treatment. Comella et  al. (1992) 
found that EMG assistance did not further increase the 
number of patients improving compared with those 
injected clinically. The striking difference between 
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Fig. 1 Flow diagram showing progression of subjects from screening
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marked improvement as well as the greater magnitude 
of improvement in those patients injected with EMG 
assistance. Currently, the efficacy of various injection 
techniques is evaluated within 12 weeks following treat-
ment. In the present study, no significant difference was 
observed in the Tsui score between groups at 12  weeks 
post-treatment. However, the Tsui score was higher in 
patients receiving palpation-guided injections than that 
in patients receiving EMG-guided injections 16  weeks 
after treatment. This may be owing to more accurate 
identification of spasmodic muscles facilitated by EMG-
guided injection, which allows more drugs at the same 
dose to act on the motor end plates, thereby resulting 
in prolonged efficacy. However, whether EMG-guided 
injection can prolong efficacy duration requires further 
investigation.
In the present study, the effect of injections using two 
techniques on neck pain in CD was studied. Our results 
showed no significant difference in pain between the two 
injection techniques at each time point during follow-up. 
Pain relief was not parallel to the improvement in clini-
cal symptoms. While a significant difference in Tsui score 
was observed between groups 16  weeks after therapy, 
no significant difference in VAS scores was observed. 
Consistent with previous studies, the majority of CD 
patients presented with symptoms of neck pain. It has 
been reported that neck pain was significantly relieved in 
majority of patients with dystonia after botulinum toxin 
type A therapy (Brin et al. 1988). A study using a masti-
catory muscle model demonstrated that botulinum toxin 
type A can relieve pain caused by muscle spasm, and 
that the analgesic effect remains when muscle tension is 
restored (Freund and Schwartz 2003). In addition, botu-
linum toxin type A exerts a significant effect on various 
pain disorders, including trigeminal neuralgia (Wu et al. 
2012) and migraines (Aurora et  al. 2010; Diener et  al. 
Table 1 Demographic and baseline clinical characteristics
Parameter Group A Group B Total
Age (years)
 Mean (SD) 44.5 (11.0) 43.1(10.7) 43.7 (10.7)
 Median 46 42 43.5
 Min/max 21/66 26/69 21/69
Female, N (%) 22 (68.8 %) 23 (63.8 %) 46 (66.2 %)
Weight (kg)
 Mean (SD) 64.7 (6.9) 65.8 (7.8) 65.3 (7.3)
 Median 65 65.5 65.5
 Min/max 49/80 51/81 49/81
CD duration (years)
 Mean (SD) 6.0 (2.5) 5.8 (2.0) 6.0 (2.2)
 Median 6 6 6
 Min/max 1/12 1/9.5 1/12
TSUI scale
 Mean (SD) 12.6 (2.9) 13.7 (3.0) 13.2 (3.0)
 Median 12 13.5 13
 Min/max 9/19 9/19 9/19
HADS-anxiety
 Mean (SD) 7.9 (4.2) 7.6 (4.4) 7.7 (4.3)
 Median 8 6.5 8
 Min/max 0/17 0/16 0/17
HADS-depression
 Mean (SD) 8.3 (3.7) 8.5 (3.9) 8.5 (3.8)
 Median 9 8.5 9
 Min/max 0/13 2/17 0/17
OnabotulinumtoxinA dose
 Mean (SD) 247.2 (35.1) 257.4 (40.1) 252.6 (37.9)
 Median 250 265 257.5
 Min/max 165/300 150/320 150/320
Fig. 2 Changes in Tsui score
Table 2 Neck pain as measured by VAS, mean (SD)
Group A Group B Total
Baseline 3.0 (3.1) 3.3 (3.2) 3.2 (3.1)
Week 4 1.0 (1.4) 0.7 (1.2) 0.8 (1.3)
Week 8 1.1 (1.6) 0.9 (1.4) 1.0 (1.5)
Week 12 1.4 (1.6) 1.3 (1.3) 1.3 (1.5)
Week 16 1.9 (2.1) 2.5 (2.4) 2.1 (2.3)
Table 3 Summary of adverse events, N (%) of patients
Adverse events Group A Group B
Dysphagia 10 (31.3 %) 6 (16.7 %)
Neck muscle weakness 5 (15.6) 6 (16.7 %)
Discomfort at injection site 3 (9.4 %) 7 (19.4)
Dry mouth 2 (6.3 %) 3 (8.3 %)
Patients with ≥1 adverse events 17 (53.1 %) 19 (52.8 %)
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2010). However, the mechanism by which botulinum 
toxin type A relieves pain remains unclear. Its efficacy in 
both spasmodic and non-spasmodic pain suggests that 
the effectiveness of botulinum toxin type A in neck pain 
relief in CD patients might not be associated with the 
mechanism of dystonia alleviation. Studies have shown 
that the effectiveness of botulinum toxin type A in neck 
pain relief may be associated with its inhibitory effects 
on meningeal nociceptors, which prevents or reverses 
C-fiber-mediated mechanical hypersensitivity (Schulte 
and May 2015).
Previous studies have shown that CD significantly 
affects patient quality of life (Comella and Bhatia 2015). 
In the present study, more than half of the patients pre-
sented with anxiety and depressive disorders, which may 
affect quality of life. Our results demonstrated that the 
HADS score 8 weeks after treatment was not significantly 
different from that prior to treatment between groups, 
even though clinical symptoms significantly improved. 
These results partly explain the higher proportion of 
“very much improved” or “much improved” ratings with 
CGIC, than that observed using PGIC, since ratings may 
be distorted owing to self-evaluation. These findings 
suggest that attention is required in clinical practice to 
simultaneously treat anxiety and depression associated 
with CD, thereby achieving optimal outcomes.
Botulinum toxin type A was generally well tolerated 
in this study population. The incidence of dysphagia was 
significantly lower, whereas the incidence of discomfort 
at the injection site was significantly higher in the group 
of patients receiving EMG-guided injection. These results 
may have been owing to increased accuracy of injection 
facilitated by EMG guidance, thereby resulting in less dif-
fusion of the drug to the muscles of the throat (Werdelin 
et  al. 2011). Compared with palpation-guided injection, 
EMG-guided injection requires more complicated proce-
dures, in which repeated adjustment of the needle elec-
trode position may result in discomfort at the injection 
site in patients. Because doses of different formulations of 
Botulinum toxin type A are not interchangeable, it is not 
clear whether other formulates of Botulinum toxin type A 
can exert the same effects. Although we found that 1U of 
the Botulinum toxin type A we used herein corresponds 
to 1 U of commercially available Botox (Allergan, Inc.) in 
the treatment of blepharospasm and hemifacial spasm 
(Wu et al. 2011), more studies are needed to evaluate the 
effective dose of other formulations of Botulinum toxin 
type A in the management of CD (Wu et al. 2012).
In summary, our 16-week follow-up, randomized, 
controlled trial indicated that CD patients treated 
with EMG guidance experienced a prolonged benefit 
as measured by the Tsui scale when compared to CD 
patients treated with palpation guidance alone. CD 
patients treated with EMG guidance experienced a sig-
nificantly more pain at the injection site but a signifi-
cantly lower adverse event occurrence rate of dysphagia 
when compared to CD patients treated with palpation 
guidance only.
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